Neurogene Inc. NGNE
22.93 USD -0.21 (-0.91%)
Regular-session close
23.50 +0.57 +2.49%
After hours · Nov 19, 5:15 PM ET
22.52 Day range 23.36
15.93 52-week range 43.66
- YTD
- +11.31%
- 1 year
- +9.24%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 52.80 +130.3% upside
Now 22.93
- Target (low)
- 45.00
- Target (mean)
- 52.80
- Target (high)
- 72.00
Ratings (0m) 7 7 buy · 0 hold · 0 sell
- Strong buy2
- Buy5
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 7
- 1 month ago 7
- 2 months ago 7
Included in Essentials and up
Sign in to see Revenue and earnings forecast
Reported revenue and earnings per share by year, then what analysts expect next.
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 0 | 0.0% | 0 |
| Next quarter | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 0 | 0.0% | 0 |
| Current year | -3.86 | -3.86 – -3.86 | 0.00 | 0.0% | 770.83K | 0.0% | 1 |
| Next year | -3.90 | -3.90 – -3.90 | -3.86 | -1.0% | 0 | -100.0% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 25, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Nov 20, 2024 | BMO Capital | Maintained | Outperform | Outperform |
| Nov 19, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Nov 12, 2024 | Stifel | Maintained | Buy | Buy |
| Nov 12, 2024 | BMO Capital | Maintained | Outperform | Outperform |
| Nov 12, 2024 | Leerink Partners | Maintained | Outperform | Outperform |
| Nov 12, 2024 | Baird | Maintained | Outperform | Outperform |
| Nov 12, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 12, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jun 27, 2024 | BMO Capital | Initiated | — | Outperform |
| Jun 20, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jun 11, 2024 | Baird | Initiated | — | Outperform |
| Jun 4, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 13, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| May 8, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 3, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Apr 29, 2024 | Leerink Partners | Initiated | — | Outperform |
| Mar 21, 2024 | William Blair | Initiated | — | Outperform |
| Mar 19, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 5, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jan 17, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jan 8, 2024 | HC Wainwright & Co. | Initiated | — | Buy |
| Jan 5, 2024 | Stifel | Initiated | — | Buy |
Included in Plus and up
Sign in to see Analyst trend
Two years of the analyst rating mix and the average price target against the price.
